264 related articles for article (PubMed ID: 25164260)
1. Maternal and foetal adverse events with tumour necrosis factor-alpha inhibitors in inflammatory bowel disease.
Deepak P; Stobaugh DJ
Aliment Pharmacol Ther; 2014 Nov; 40(9):1035-43. PubMed ID: 25164260
[TBL] [Abstract][Full Text] [Related]
2. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
3. Tumor necrosis factor α antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system.
Kip KE; Swoger JM; Grandinetti LM; Barrie AM; Greer JB; Regueiro MD
Inflamm Bowel Dis; 2013 May; 19(6):1164-72. PubMed ID: 23518804
[TBL] [Abstract][Full Text] [Related]
4. Infectious complications of TNF-α inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System.
Deepak P; Stobaugh DJ; Ehrenpreis ED
J Gastrointestin Liver Dis; 2013 Sep; 22(3):269-76. PubMed ID: 24078983
[TBL] [Abstract][Full Text] [Related]
5. Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-α inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System.
McKenna MR; Stobaugh DJ; Deepak P
J Gastrointestin Liver Dis; 2014 Sep; 23(3):267-71. PubMed ID: 25267954
[TBL] [Abstract][Full Text] [Related]
6. Effect of tumor necrosis factor-α inhibitors on drug-induced pancreatitis in inflammatory bowel disease.
Stobaugh DJ; Deepak P
Ann Pharmacother; 2014 Oct; 48(10):1282-7. PubMed ID: 24982311
[TBL] [Abstract][Full Text] [Related]
7. IBD: Can TNF inhibitors be administered during the third trimester?
Nielsen OH; Jess T
Nat Rev Gastroenterol Hepatol; 2013 Mar; 10(3):130-1. PubMed ID: 23247511
[No Abstract] [Full Text] [Related]
8. Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System.
Deepak P; Stobaugh DJ; Sherid M; Sifuentes H; Ehrenpreis ED
Aliment Pharmacol Ther; 2013 Aug; 38(4):388-96. PubMed ID: 23802849
[TBL] [Abstract][Full Text] [Related]
9. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease.
Mahadevan U; Wolf DC; Dubinsky M; Cortot A; Lee SD; Siegel CA; Ullman T; Glover S; Valentine JF; Rubin DT; Miller J; Abreu MT
Clin Gastroenterol Hepatol; 2013 Mar; 11(3):286-92; quiz e24. PubMed ID: 23200982
[TBL] [Abstract][Full Text] [Related]
10. [Anti-tumor necrosis factor-α medications and pregnancy].
Simon PC; Vallano A
Med Clin (Barc); 2013 Sep; 141(6):257-9. PubMed ID: 23702347
[No Abstract] [Full Text] [Related]
11. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD
J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978
[TBL] [Abstract][Full Text] [Related]
12. Certolizumab pegol for the management of Crohn's disease in adults.
Rivkin A
Clin Ther; 2009 Jun; 31(6):1158-76. PubMed ID: 19695385
[TBL] [Abstract][Full Text] [Related]
13. Safety of TNF-α inhibitors during IBD pregnancy: a systematic review.
Nielsen OH; Loftus EV; Jess T
BMC Med; 2013 Jul; 11():174. PubMed ID: 23902720
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
Mitoma H; Horiuchi T; Tsukamoto H; Ueda N
Cytokine; 2018 Jan; 101():56-63. PubMed ID: 27567553
[TBL] [Abstract][Full Text] [Related]
15. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.
Gisbert JP; Marín AC; McNicholl AG; Chaparro M
Aliment Pharmacol Ther; 2015 Apr; 41(7):613-23. PubMed ID: 25652884
[TBL] [Abstract][Full Text] [Related]
16. Higher risk of tuberculosis reactivation when anti-TNF is combined with immunosuppressive agents: a systematic review of randomized controlled trials.
Lorenzetti R; Zullo A; Ridola L; Diamanti AP; Laganà B; Gatta L; Migliore A; Armuzzi A; Hassan C; Bruzzese V
Ann Med; 2014 Nov; 46(7):547-54. PubMed ID: 25105206
[TBL] [Abstract][Full Text] [Related]
17. [Certolizumab pegol].
Delgado Frías E; Díaz González JF
Reumatol Clin; 2011 Mar; 6S3():S7-11. PubMed ID: 21794764
[TBL] [Abstract][Full Text] [Related]
18. Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease.
Mocci G; Marzo M; Papa A; Armuzzi A; Guidi L
J Crohns Colitis; 2013 Nov; 7(10):769-79. PubMed ID: 23453887
[TBL] [Abstract][Full Text] [Related]
19. New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease.
Shelton E; Chaudrey K; Sauk J; Khalili H; Masia R; Nguyen DD; Yajnik V; Ananthakrishnan AN
Aliment Pharmacol Ther; 2015 May; 41(10):972-9. PubMed ID: 25756190
[TBL] [Abstract][Full Text] [Related]
20. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]